we may be able to start directly a phase 2 clinical study in 2025.” That trial is now off the menu, as Basilea has completed its own preclinical profiling of the medicine and “taken the ...

Basilea Pharmaceutica may finally be able to ... first FDA-approved therapy for idiopathic macular telangiectasia type 2.

Kaul confirmed interest in late preclinical to Phase 2 assets in antifungals and antibacterials ... non-dilutive funding to offset R&D expenses. Basilea reported robust financial results for ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced ...

Fosmanogepix is due to start two phase 3 trials this year, with BAL2062 heading for a phase 2 study in 2025. Basilea has an option on tonabacase and has said it plans to decide on that if ...

by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 2.5 million milestone payment. David Veitch, Basilea’s Chief Executive ...

Earnings Call Insights: Basilea Pharmaceutica AG (OTC ... Kaul confirmed interest in late preclinical to Phase 2 assets in antifungals and antibacterials. Thomas Meyer, Baader Helvea: Queried ...

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial ...